Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells

Abstract

Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and histone deacetylase (HDAC) inhibitors have recently emerged as promising anticancer drugs. The aim of this study was to investigate the effect of combination treatment with the PARP inhibitor PJ34 and HDAC inhibitor SAHA on the proliferation of liver cancer cells. Cell proliferation and apoptosis were assessed in three human liver cancer cell lines (HepG2, Hep3B and HCC-LM3) treated with PJ34 (8 μmol/L) and SAHA (1 μmol/L), alone or combined, by Cell Counting Kit-8 assay and flow cytometry, respectively. The nude mice bearing subcutaneous HepG2 tumors were administered different groups of drugs (10 mg/kg PJ34, 25 mg/kg SAHA, 10 mg/kg PJ34+25 mg/kg SAHA), and the inhibition rates of tumor growth were compared between groups. The results showed that combined use of PJ34 and SAHA could synergistically inhibit the proliferation of liver cancer cell lines HepG2, Hep3B and HCC-LM3. The apoptosis rate of HepG2 cells treated with PJ34+SAHA was significantly higher than that of HepG2 cells treated with PJ34 or SAHA alone (P<0.05). In vivo, the tumor inhibition rates were 53.5%, 61.4% and 82.6% in PJ34, SAHA and PJ34+SAHA groups, respectively. The combined use of PJ34 and SAHA could significantly inhibit the xenograft tumor growth when compared with use of PJ34 or SAHA alone (P<0.05). It was led to conclude that PJ34 and SAHA can synergistically suppress the proliferation of liver cancer cells.

Keywords

poly (ADP-ribose) polymerase-1 / PJ34 / histone deacetylase / SAHA / liver cancer / proliferation

References

[1] LafaroKJ, DemirjianAN, PawlikTM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am, 2015, 24(1): 1-17 PMID: 25444466

[2] BruixJ, GoresGJ, MazzaferroV. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, 63(5): 844-855 PMCID: 4337888 PMID: 24531850

[3] MaL, ChuaMS, AndrisaniO, et al. . Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol, 2014, 20(2): 333-345 PMCID: 3923010 PMID: 24574704

[4] YangSF, ChangCW, WeiRJ, et al. . Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int, 2014, 2014: 153867 PMCID: 4022277 PMID: 24877058

[5] BeckC, RobertI, Reina-San-MartinB, et al. . Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3. Exp Cell Res, 2014, 329(1): 18-25 PMID: 25017100

[6] McCabeN, TurnerNC, LordCJ, et al. . Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res, 2006, 66(16): 8109-8115 PMID: 16912188

[7] BastRCJr, MillsGB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol, 2010, 28(22): 3545-3548 PMID: 20547987

[8] De SummaS, PintoR, SambiasiD, et al. . BRCAness: a deeper insight into basal-like breast tumors. Ann Oncol, 2013, 24(8): 13-21

[9] RobertT, VanoliF, ChioloI, et al. . HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature, 2011, 471(7336): 74-79 PMCID: 3935290 PMID: 21368826

[10] LahueRS, FrizzellA. Histone deacetylase complexes as caretakers of genome stability. Epigenetics, 2012, 7(8): 806-810 PMCID: 3427275 PMID: 22722985

[11] ClampA, JaysonG. PARP inhibitors in BRCA mutation-associated ovarian cancer. Lancet Oncol, 2015, 16(1): 10-12 PMID: 25481790

[12] HuangSH, XiongM, ChenXP, et al. . PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells. Oncol Rep, 2008, 20(3): 567-572 PMID: 18695907

[13] NogamiY, BannoK, KisuI, et al. . Current status of molecular-targeted drugs for endometrial cancer. Mol Clin Oncol, 2013, 1(5): 799-804 PMCID: 3915661 PMID: 24649249

[14] Gourzones-DmitrievC, KassambaraA, SahotaS, et al. . DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle, 2013, 12(17): 2760-2773 PMCID: 3899190 PMID: 23966156

[15] BoseP, DaiY, GrantS. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther, 2014, 143(3): 323-336 PMID: 24769080

[16] Garcia-ManeroG, YangH, Bueso-RamosC, et al. . Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 2008, 111(3): 1060-1066 PMID: 17962510

[17] LeeJH, ChoyML, NgoL, et al. . Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA, 2010, 107(33): 14639-14644 PMCID: 2930422 PMID: 20679231

[18] AlliE, Solow-CorderoD, CaseySC, et al. . Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res, 2014, 74(21): 6205-6215 PMID: 25217519

[19] PothuriB. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol, 2013, 24(8): 22-27

[20] DuvicM, TalpurR, NiX, et al. . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 2007, 109(1): 31-39 PMCID: 1785068 PMID: 16960145

[21] ZhouC, JiJ, ShiM, et al. . Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatininduced Src activation in gastric cancer cells. Mol Med Rep, 2014, 10(5): 2729-2735 PMID: 25199623

[22] XiaoW, GrahamPH, HaoJ, et al. . Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One, 2013, 8(8): 74253

[23] AdimoolamS, SirisawadM, ChenJ, et al. . HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA, 2007, 104(49): 19482-19487 PMCID: 2148315 PMID: 18042714

[24] LiX, ChenBD. Histone deacetylase inhibitor M344 inhibits cell proliferation and induces apoptosis in human THP-1 leukemia cells. Am J Biomed Sci, 2009, 1(4): 352-363 PMCID: 2880493 PMID: 20526416

[25] PetruccelliLA, PetterssonF D R S, et al. . Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitorinduced DNA damage and apoptosis. Mol Cancer Ther, 2013, 12(8): 1591-1604 PMID: 23536727